Methods:
The PubMed database was searched using the keyword ''mexazolam'' with no date or language restrictions applied to the search. As only 11 papers were retrieved, some previously published manuscripts of interest known by the authors (not indexed on PubMed) have been added for completeness. Relevant information was selected for inclusion by the authors.
Results:
A number of early studies demonstrated the ability of mexazolam to reduce anxiety symptoms with few side effects in patients with disorders associated with anxiety. Following on from this preliminary evidence, controlled studies directly comparing mexazolam with other BZDs showed that the drug is more effective than bromazepam and oxazolam, and is at least as effective as alprazolam. A larger, multicenter, phase IV study also showed that mexazolam 2 or 3 mg/ day rapidly improved Hamilton Anxiety Rating Scale scores and substantially reduced the frequency and severity of numerous somatic anxiety symptoms in patients with anxiety disorders. With regard to safety, the clinical evidence indicates that mexazolam is generally well tolerated, with a low incidence of drowsiness and sedation. Furthermore, the lack of psychomotor or cognitive performance impairment following mexazolam administration may lead to better treatment compliance.
Electronic supplementary material The online version of this article (doi:10.1007/s40120-014-0016-7) contains supplementary material, which is available to authorized users.
INTRODUCTION
Epidemiological research has indicated that anxiety disorders are among the most common psychiatric disorders in the United States [1] [2] [3] . Furthermore, data from a World Health Organization World Mental Health survey reported anxiety disorders to be the most common mental disorder (estimated lifetime prevalence of 4.8-31.0%) in numerous countries across Africa, Asia, the Americas, Europe, and the Middle East [4] .
The most commonly occurring anxiety disorders include generalized anxiety disorder, panic attacks, panic disorder, specific phobia, social anxiety disorder, agoraphobia, traumaand stressor-related disorders, obsessivecompulsive and related disorders, separation anxiety disorder, and illness anxiety disorder [5] . These disorders are marked by excessive fear, anxiety, and associated avoidance behaviors, but are distinguished from each other by the types of objects or situations that induce the fear or avoidance. Anxiety disorders are marked by persistence, rather than transient fear or anxiety, and tend to have their onset in childhood or adolescence (Diagnostic and Statistical Manual of Mental Disorders
[DSM]-5) [5] .
Following an accurate diagnosis, the recommended treatment options for anxiety disorders include psychotherapies and pharmacological therapies [6] [7] [8] .
Benzodiazepines (BZDs) are a class of drugs that bind to specific BZD-type receptors on the gamma-aminobutyric acid (GABA) chloride ion complex and facilitate GABA inhibitory effects [9, 10] . Although BZDs are not generally recommended for first-line, long-term management of anxiety disorders in clinical practice, their use as second-line treatment is widespread [11] .
In 1956, Dr. Leo Sternbach discovered the first BZD, chlordiazepoxide (approved in 1960), which was followed by the release of its congener, diazepam, in 1963 [11] . Since the release of chlordiazepoxide and diazepam, more than 1,000 BZDs have been synthesized. [11] .
More recently, four non-BZD hypnotics (zaleplon, zolpidem, zopiclone, and eszopiclone), also known as the so-called z-drugs, were introduced. Although these compounds are effective for the initial treatment of insomnia, their clinical effects are not sustained through the night [11] .
Today, there are a wide range of BZDs available for use in clinical practice. Despite sharing the same mechanism of action, they vary in their duration of action (short-vs. longacting) and difference in pharmacokinetic profiles translate, in clinical practice, into differences in their main therapeutic effect (anxiolytic vs. hypnotic) [11, 12] . BZDs with a strong anxiolytic effect at therapeutic doses, such as diazepam, are effective for the relief of anxiety states, while BZDs with a predominant hypnotic effect, such as flurazepam, are used for the short-term treatment of insomnia [11] .
BZDs such as clonazepam are also associated with anticonvulsant effects [13] .
In addition to their clinical effectiveness, one of the main advantages of BZDs in the treatment of anxiety is their early onset of action [14] , which may explain why these agents continue to be widely prescribed. However, BZDs may be associated with a number of adverse effects, particularly at higher doses, which include sedation, physical and psychic dependence, and impaired concentration, memory and psychomotor performance [14] . Furthermore, withdrawal symptoms and rebound anxiety may be associated with the long-term use of these agents [14] . The frequency and severity of these adverse events may also vary between BZDs. BZDs have also been linked to substance abuse/misuse and dependence when used longterm [15] .
With the current availability of a variety of 
MEXAZOLAM
Mexazolam (also known as CS-386) is currently indicated for the management of anxiety with or without psychoneurotic conditions when the disorder is severe, disabling, or subjecting the individual to extreme distress [16] . The duration of treatment should be as short as possible and the dosage of mexazolam should be adjusted based on an individual patient's age and the severity of symptoms. In adults, the average daily dose is 1-3 mg, which is preferably administered three times daily (TID); the daily dosage should not exceed 1.5 mg in elderly patients. Mexazolam is not indicated for use in pediatric patients [16] .
Chemical Properties
oxazolo-BZD that is structurally similar to oxazolam and cloxazolam [17] .
Pharmacokinetic Considerations
After [16, 18] . The active metabolite, COX, represents more than 50% of the total amount of excreted metabolites, and is essentially found as a conjugate [16, 19] .
Although only small amounts of mexazolam may be found in breast milk, the drug should not be given to breast feeding mothers [16, 19] .
Preclinical Studies
Like cloxazolam and oxazolam, mexazolam demonstrated a broad safety profile and very low acute toxicity in preclinical studies. The results of studies conducted in rats reported that the subacute or chronic administration of mexazolam showed no toxic reactions below a dosage of 125 mg/kg [16, 20] . Teratogenicity and mutagenic tests were negative, and preclinical animal studies did not indicate any harmful effects for mexazolam during pregnancy [16, 17] . However, the safety of this drug in humans has not been established during pregnancy.
Preclinical studies showed that mexazolam was 2-3 times more effective than diazepam and cloxazolam at improving performance in conflict behavior or lever-pressing tests (regarded as a measure of an antianxiety effect) [21, 22] . Mexazolam was also shown to inhibit megimide-induced convulsions in mice [23] . In electrophysiological tests using cats, mexazolam showed a stronger action than those of cloxazolam and diazepam with respect to the cerebral marginal gyrus, especially the amygdaloid nucleus, which plays important roles in instinctive behavior and emotional activity. Concomitant side effects such as drowsiness, muscle relaxation, and motor ataxia are weaker than those of diazepam and cloxazolam [23] . The results of preclinical studies also showed that mexazolam appears to have a more potent antianxiety effect than cloxazolam and diazepam, while causing less muscular relaxation, sedation, and ataxia [23, 24] .
Clinical Studies
Mexazolam has been extensively studied for the treatment of anxiety disorders, and the results of a number of clinical trials have been published. Phase I and II trials reported that mexazolam was associated with a reduction in anxiety symptoms and few side effects [25] [26] [27] [28] [29] [30] .
A phase III, multicenter, double-blind, randomized study of 165 patients with psychosomatic disorders or neurosis confirmed the antianxiety effect of mexazolam (final global improvement rates of 75.6% and 63.8% with mexazolam and oxazolam, respectively) [31] . Based on these results, the authors concluded that mexazolam appeared to be a more effective drug than oxazolam.
A number of additional studies have since been conducted to determine the clinical efficacy and tolerability of mexazolam.
Clinical Efficacy
Katsunuma et al. [23] Efficacy was assessed at 0, 14, and 28 days using the HAM-A scale and investigator-reported global clinical evaluation of the patient.
Significant reductions in HAM-A scores were seen in both treatment groups at Days 14 and 28 ( Fig. 1) . Furthermore, the reductions were greater in patients treated with mexazolam. These results appeared to translate to an overall improvement in patient functioning for both study drugs, although this improvement was statistically higher with mexazolam [33] . [17] . Mexazolam also reduced the 27 somatic anxiety symptoms that were evaluated. Greater percent reductions in frequency and severity were noted for asthenia, headache, distractedness, irritability, restlessness, palpitations, and chest tightness (Table 1) . At study end, the improvement in symptoms was considered to be ''excellent'' or ''very good'' in 65% of patients, ''fair'' in 24%, and ''null'' in 11% [17] . Vaz-Serra et al. baseline), with no significant between-group differences [34] . Furthermore, the beneficial anxiolytic effects of mexazolam and alprazolam were sustained during the tapering and withdrawal periods, as shown by the CGI-DSS mean scores remaining significantly lower than baseline in both treatment groups. As with the HAM-A score, CGI-global improvement score (CGI-GIS) responder rates (the proportion of patients who were ''highly improved'' or ''moderately improved'') were higher in the mexazolam group compared with the alprazolam group at the end of weeks 1 (54.8% vs. 46.7%) and 3 (96.7% vs. 86.7%); however, these differences did not reach statistical significance [34] .
Clinical Tolerability
With regard to tolerability, Katsunuma et al.
[23] reported a mild degree of drowsiness in 5 of the 29 patients (17.2%). In addition, no falls were reported.
In the study conducted by Ohara et al. [32] , mexazolam-related side effects were reported in 11 of the 44 patients (25.0%); drowsiness was the most frequently reported side effect (7 patients). No serious side effects requiring a reduction in dosage were reported [32] . In addition, no abnormalities in clinical laboratory tests (including hematological and urinalysis findings) were seen in the 24 patients who underwent testing before and after the completion of mexazolam therapy.
In the study published by Vaz-Serra [33] in 1993, no side effects were reported in the majority of patients; side effects were generally minor in terms of severity, and did not alter the general state of the patient. In a clinical assessment of general symptoms that could be considered to be side effects, no significant changes in these symptoms were seen prior to versus during mexazolam therapy. Asthenia and sedation were the symptoms most frequently reported during the study. Vaz-Serra [33] also assessed memory changes, which are often adversely affected by the use of BZDs. Memory changes were evaluated using the digit span test (the ability of a patient to fix and immediately reproduce a sequence of five numbers, repeating this procedure three times in each observation) and a questionnaire to evaluate memory retention and recall [33] . The results showed no detrimental alterations in patient memory; in fact, a significant improvement in the digit span test was seen for mexazolam versus bromazepam (P = 0.015). This finding suggests that the improvement in anxiety levels may lead to improvements in the capacity to retain and subsequently recall messages.
In the phase IV study conducted by Vieira Coelho and Garrett [17] , the overall incidence of side effects was 11.7% at Day 28, with the most frequent event being daytime sedation (7.5% of patients). The investigator-rated intensity of side effects was considered to be inconsequential in 65% of patients and mild in 31%; side effects that interfered with normal daily activity were reported in 4% of patients.
The effect of mexazolam on cognition and memory performance was evaluated by an objective test [Negative Symptom Rating Scale: B-cognition III x-Memory (NSRS)], which showed no impairment of cognitive function during the study. Similar to the Vaz-Serra [33] 1993 study, enhanced performance on the memory test, demonstrated by significant improvements from Day 0 in NSRS scores at Days 7 and 28 (both P\0.05) was observed in patients receiving mexazolam and authors again indicated that memory improvement was likely to be related to the anxiolytic effect of mexazolam (Fig. 3) [17] .
In 2001, the study by Vaz-Serra et al. [34] reported no clinically important differences in tolerability between mexazolam and alprazolam. Adverse events in both treatment groups were mild to moderate in intensity and consistent with the well-known tolerability profile of BZDs. The most commonly reported event was drowsiness, which occurred in 9.7% and 10.0% of patients receiving mexazolam and alprazolam, respectively.
In addition to the safety issues described above, BZD use has been associated with impaired psychomotor function, resulting in the disruption of tasks that require sustained attention, vigilance, speed, and accuracy [35] [36] [37] . Preclinical studies indicate that although the anxiolytic properties of mexazolam are similar to those of diazepam and cloxazepam, mexazolam produces less sedation, ataxia, and muscular relaxation [38] . This suggests that mexazolam may be associated with fewer deleterious effects on psychomotor performance and cognitive function than other BZDs. It was in this context that Silveira et al. [18] conducted a double-blind, randomized, two-way crossover, placebocontrolled study in 33 healthy adult volunteers to assess the effect of a single 1-mg oral dose of mexazolam on psychomotor performance. Psychomotor performance was No statistically significant differences were seen between mexazolam and placebo with regard to the LPT Battery results (CFF, RRT, MRT, and TRT) [24] . Regarding HAM-A assessment, significant improvements in total and somatic scores were seen with mexazolam versus placebo at Day 7, but not at Day 21. However, it should be noted that sample size was estimated on the basis of the CFF parameter, and that high-dose regimens of well-established drugs such as diazepam have also shown this phenomenon. The most frequently reported adverse event was 
DISCUSSION
To our knowledge this is the first review of articles to be conducted for mexazolam. Despite the wide availability of BZDs and their rapid onset of action, selective serotonin reuptake inhibitors (SSRIs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) are the recommended first-line agents for anxiety due to their favorable risk-benefit ratio, with
BZDs used as an adjunct to SSRIs and SNRIs in the first few weeks of treatment (for control of short-term anxiety or when deemed necessary by the clinician [6] . BZDs can be a useful adjunct, as the anxiolytic effect of SSRIs and SNRIs has a delayed onset of action of 2-4 weeks, and, in some cases, up to 6-8 weeks); however, we have not found in the literature any papers describing or evaluating this specific use of mexazolam in the short-term treatment of anxiety.
Globally, BZDs have a good safety record and should be used with a regular dosing regimen but are not effective in acute stress disorder, in patients with comorbid depression, or in those with obsessive-compulsive and related disorders [6] .
Mexazolam is not mentioned specifically in the latest European guidelines, probably because it is not available in many European countries (nevertheless, it is mentioned in national guidelines of countries where the drug is available, for example, Portugal) [ Coelho and Garrett [17] ).
A second comparative study was conducted by Vaz-Serra et al. [34] [23] and Ohara et al. [32] (although the mexazolam dosages used in these two studies were higher [6 and 4 mg/day, respectively] and they were not double-blind, placebo-controlled studies). With regard to efficacy, Vaz-Serra et al. [34] concluded that mexazolam appeared to be associated with higher HAM-A and CGI-GIS responder rates versus alprazolam, although the between-group differences did not reach statistical significance. The study also showed that mexazolam had a fast onset of action (significant reductions in anxiety scores were seen in the first week of treatment) and a sustained effect throughout the study, including the tapering and treatment-free follow-up periods [34] . This short latency of the anxiolytic effect for mexazolam is clinically relevant, because it enables the rapid and consistent control of symptoms. [18] and the fact that mexazolam 1 mg is equivalent to diazepam 1 mg [46] , it is possible that mexazolam therapy may be associated with few adverse effects on cognitive function and little or no impairment of daily activities.
Furthermore, Silveira et al. [18] showed that mexazolam did not affect learning ability (no significant differences compared with placebo).
Finally, the study by Ferreira et al. [24] showed that there was an absence of 
